Trovagene Q3 Revenues Decline | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Thursday that its third quarter revenues fell to $44,000 from $211,000 year over year.

All of the firm's revenues were derived from royalties, a company official said on a conference call following the release of the results.

Trovagene posted a net loss of $4.4 million, or $.25 per share, for the three month period ended Sept. 30, compared to a net loss of $660,000, or $.05 per share, for Q3 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.